Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Clinical Cardiology 1983-Apr

Stress damage to nonischemic divisions of the heart in experimental infarction and its prevention.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Lyen an sove nan clipboard la
F Z Meerson

Mo kle

Abstrè

Recently, it has been shown that nonischemic parts of the heart in myocardial infarction were separated from ischemic damaged ones by a sharp border zone. In this connection, the disturbance of contractile function of the myocardium of nonischemic parts is suggested to result from the infarction-concomitant emotional-painful stress. In order to test this assumption, the contractile function of the right auricle, which is an a priori nonischemic heart division, was studied in rats subjected to myocardial infarction of the left ventricle. In the study of the isolated auricle the following facts were established: 1 day after the induced infarction the atrial myocardium shows reduced extensibility, depression of the Starling curve, a concomitant approximately twofold decrease of the maximal systolic tension, and a reduced myocardial resistance to hypoxia and calcium excess. This complex of shifts, first, is completely reproduced without myocardial infarction by emotional-painful stress and, second, can be prevented to a considerable extent by propranolol indicating that it is essentially stress induced. In infarction, these above said stress-induced disturbances of the contractile function of nonischemic divisions of the heart were found to be prevented or limited by factors stabilizing the membranous lipid bilayer of cardiomyocytes, i.e., by antioxidant ionol, by nicotinamide, a lipase inhibitor, and by chloroquine, a phospholipase inhibitor. The aspects of application of these factors for the therapy of ischemic heart disease requires further studies.

Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge